

Leonard B Saltz

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1606570/leonard-b-saltz-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

421 papers	43,748 citations	111 h-index	203 g-index
459 ext. papers	51,424 ext. citations	6.4 avg, IF	6.94 L-index

#	Paper	IF	Citations
4 ²¹	Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. <i>New England Journal of Medicine</i> , 2000 , 343, 905-14	59.2	2534
4 ²⁰	Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2013-9	2.2	2328
4 ¹⁹	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017 , 23, 703-713	50.5	1638
4 ¹⁸	Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1201-8	2.2	1492
4 ¹⁷	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019 , 51, 202-206	36.3	1435
4 ¹⁶	Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4293-300	2.2	1002
4 ¹⁵	Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1803-10	2.2	943
4 ¹⁴	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017 , 2017,	3.6	699
4 ¹³	Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2006-12	2.2	667
4 ¹²	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2563-77	2.2	599
4 ¹¹	Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3535-41	2.2	567
4 ¹⁰	Hepatic neuroendocrine metastases: does intervention alter outcomes?. <i>Journal of the American College of Surgeons</i> , 2000 , 190, 432-45	4.4	539
4 ⁰⁹	Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 370-398	7.3	485
4 ⁰⁸	Developing a cancer-specific geriatric assessment: a feasibility study. <i>Cancer</i> , 2005 , 104, 1998-2005	6.4	435
4 ⁰⁷	NCCN Guidelines Insights: Colon Cancer, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 359-369	7.3	433
4 ⁰⁶	Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5235-46	2.2	430
4 ⁰⁵	Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 874-901	7.3	429

404	Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4032-8	2.2	424
403	Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2925-34	2.2	384
402	Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3456-61	2.2	351
401	Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4557-61	2.2	349
400	Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 304, 2154-60	27.4	344
399	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. <i>Cancer Cell</i> , 2018 , 33, 125-136.e3	24.3	338
398	The camptothecins. <i>Lancet, The</i> , 2003 , 361, 2235-42	4.0	336
397	NCCN Clinical Practice Guidelines in Oncology: colon cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7, 778-831	7.3	325
396	Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. <i>Journal of Clinical Oncology</i> , 1999 , 17, 600-6	2.2	317
395	Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3379-84	2.2	308
394	Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. <i>Journal of Clinical Oncology</i> , 2014 , 32, 513-8	2.2	303
393	Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1814-21	2.2	301
392	Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. <i>Annals of Surgery</i> , 2005 , 241, 829-36; discussion 836-8	7.8	301
391	Primary tumor location as a prognostic factor in metastatic colorectal cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	298
390	Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 298, 754-64	27.4	294
389	Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. <i>Journal of the American College of Surgeons</i> , 2002 , 194, 131-5; discussion 135-6	4.4	291
388	Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. <i>Annals of Surgery</i> , 2012 , 256, 965-72	7.8	259
387	Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. <i>Lancet Oncology, The</i> , 2016 , 17, 1709-1719	21.7	258

386	Advanced hepatocellular carcinoma: which staging systems best predict prognosis?. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2889-95	2.2	242
385	Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. <i>Cancer</i> , 1993 , 72, 244-8	6.4	242
384	Neuroendocrine tumors, version 1.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 78-108	7.3	241
383	Neuroendocrine carcinomas of the colon and rectum. <i>Diseases of the Colon and Rectum</i> , 2004 , 47, 163-9	3.1	241
382	NCCN Clinical Practice Guidelines in Oncology: rectal cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7, 838-81	7.3	240
381	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 825-835	27.4	235
380	HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. <i>Oncologist</i> , 2005 , 10, 345-56	5.7	232
379	Comparative genomic analysis of primary versus metastatic colorectal carcinomas. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2956-62	2.2	225
378	Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. <i>Genome Biology</i> , 2014 , 15, 454	18.3	224
377	Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. <i>Journal of Clinical Oncology</i> , 2002 , 20, 4673-8	2.2	224
376	Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5390-6	2.2	223
375	Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. <i>Clinical Cancer Research</i> , 2012 , 18, 890-900	12.9	219
374	Genomic and biological characterization of exon 4 KRAS mutations in human cancer. <i>Cancer Research</i> , 2010 , 70, 5901-11	10.1	218
373	Extracellular metabolic energetics can promote cancer progression. <i>Cell</i> , 2015 , 160, 393-406	56.2	217
372	Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3485-90	2.2	216
371	Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. <i>Journal of Clinical Oncology</i> , 1999 , 17, 3270-5	2.2	215
370	Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. <i>Annals of Surgery</i> , 2002 , 236, 75-81	7.8	214
369	Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. <i>JAMA Oncology</i> , 2018 , 4, e180071	13.4	205

368	Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. <i>Diseases of the Colon and Rectum</i> , 2004 , 47, 279-86	3.1	205
367	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 286-295	2.2	203
366	Individualized prediction of colon cancer recurrence using a nomogram. <i>Journal of Clinical Oncology</i> , 2008 , 26, 380-5	2.2	202
365	Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4109-15	2.2	201
364	Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. <i>Clinical Cancer Research</i> , 2018 , 24, 1326-1336	12.9	198
363	Cetuximab therapy and symptomatic hypomagnesemia. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 1221-4	9.7	195
362	Potential regional differences for the tolerability profiles of fluoropyrimidines. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2118-23	2.2	194
361	The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. <i>Investigational New Drugs</i> , 2008 , 26, 45-51	4.3	192
360	Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3999-4005	2.2	192
359	Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer. <i>Diseases of the Colon and Rectum</i> , 1997 , 40, 515-22	3.1	190
358	NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 693-702	7.3	189
357	Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. <i>Clinical Cancer Research</i> , 2015 , 21, 1313-20	12.9	189
356	Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. <i>Cancer</i> , 2008 , 113, 57-64	6.4	189
355	Use of surgery among elderly patients with stage IV colorectal cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3475-84	2.2	184
354	Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. <i>Clinical Cancer Research</i> , 2018 , 24, 4154-4161	12.9	182
353	Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1443-51	2.2	181
352	Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy. <i>JAMA Oncology</i> , 2019 , 5, e185896	13.4	180
351	Adequacy of 1-cm distal margin after restorative rectal cancer resection with sharp mesorectal excision and preoperative combined-modality therapy. <i>Annals of Surgical Oncology</i> , 2003 , 10, 80-5	3.1	177

350	Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1985-92	2.2	177
349	Colon cancer, version 3.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 1028-59	7.3	171
348	Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2600-6	2.2	171
347	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2141-7	2.2	170
346	Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1757-64	2.2	163
345	XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. <i>British Journal of Cancer</i> , 2011 , 105, 58-64	8.7	160
344	KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. <i>Clinical Cancer Research</i> , 2009 , 15, 7322-9	12.9	159
343	Rectal Cancer, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 719-28; quiz 728	7.3	154
342	Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997 , 37, 289-95	4	153
341	Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 19, 329-359	7.3	153
340	A rectal cancer organoid platform to study individual responses to chemoradiation. <i>Nature Medicine</i> , 2019 , 25, 1607-1614	50.5	149
339	Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. <i>Journal of the American College of Surgeons</i> , 2004 , 199, 1-7	4.4	149
338	Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity?. <i>American Journal of Surgical Pathology</i> , 2008 , 32, 719-31	6.7	145
337	Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2157-70	2.2	144
336	Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma		144
335	Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. <i>Annals of Thoracic Surgery</i> , 2009 , 87, 1684-8	2.7	140
334	Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. <i>British Journal of Cancer</i> , 2009 , 101, 1033-8	8.7	138
333	BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. <i>Cancer</i> , 2014 , 120, 2316-24	6.4	136

332	Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 513-9	7.3	136
331	Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001 , 49, 987-95	4	136
330	Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. <i>Journal of Clinical Oncology</i> , 2011 , 29, 83-8	2.2	135
329	Neuroendocrine tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 724-64.3	7.3	135
328	Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. <i>Annals of Surgical Oncology</i> , 2007 , 14, 759-65	3.1	135
327	Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3153-62	2.2	134
326	Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3475-9	2.2	132
325	Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010 , 136, 737-43	4.9	131
324	Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4793-9	2.2	131
323	Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. <i>Diseases of the Colon and Rectum</i> , 2000 , 43, 18-24	3.1	131
322	Rectal cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 1528-64	7.3	127
321	Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1948-55	2.2	125
320	Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. <i>Modern Pathology</i> , 2005 , 18, 1350-6	9.8	125
319	Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 1996 , 14, 2959-67	2.2	123
318	Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9073-8	2.2	121
317	Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	120
316	Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 141-52; quiz 152	7.3	118
315	Identification of germline genetic mutations in patients with pancreatic cancer. <i>Cancer</i> , 2015 , 121, 4382-8.4	8.4	117

314	Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4240-6	2.2	115
313	Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 1702-11	9.7	114
312	Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer. <i>European Radiology</i> , 2012 , 22, 821-31	8	113
311	Preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for rectal cancer. <i>Cancer</i> , 1994 , 73, 273-80	6.4	113
310	Evolving treatment of advanced colon cancer. <i>Annual Review of Medicine</i> , 2009 , 60, 207-19	17.4	111
309	Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. <i>Annals of Surgical Oncology</i> , 2001 , 8, 787-95	3.1	111
308	Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. <i>Oncologist</i> , 2001 , 6, 81-91	5.7	110
307	Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. <i>Clinical Cancer Research</i> , 2017 , 23, 6094-6100	12.9	107
306	Islet cell tumors of the pancreas: the medical oncologist's perspective. <i>Surgical Clinics of North America</i> , 2001 , 81, 527-42	4	107
305	NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 806-815	7.3	105
304	FDA Approval of Tisagenlecleucel: Promise and Complexities of a \$475 000 Cancer Drug. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 1861-1862	27.4	102
303	Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1875-84	2.2	102
302	Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107, 345	9.7	101
301	High-dose-rate intraoperative brachytherapy for recurrent colorectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000 , 48, 219-26	4	100
300	A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. <i>Clinical Cancer Research</i> , 2005 , 11, 3836-45	12.9	99
299	Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4008-4008	2.2	98
298	Oncologic outcomes of salvage surgery for epidermoid carcinoma of the anus initially managed with combined modality therapy. <i>Diseases of the Colon and Rectum</i> , 2004 , 47, 1136-44	3.1	97
297	Abdominoperineal resection for rectal cancer at a specialty center. <i>Diseases of the Colon and Rectum</i> , 2001 , 44, 27-35; discussion 35-6	3.1	97

296	CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. <i>Gastroenterology</i> , 2014 , 147, 637-45	13.3	95
295	A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer. <i>Cancer</i> , 1995 , 75, 782-5	6.4	91
294	A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. <i>British Journal of Cancer</i> , 2013 , 109, 915-9	8.7	90
293	The efficacy of preoperative 5-fluorouracil, high-dose leucovorin, and sequential radiation therapy for unresectable rectal cancer. <i>Cancer</i> , 1993 , 71, 3486-92	6.4	90
292	NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7 Suppl 1, S5-21; quiz S22-4	7.3	87
291	Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy. <i>Clinical Cancer Research</i> , 2005 , 11, 3503-13	12.9	84
290	Preoperative high-dose leucovorin/5-fluorouracil and radiation therapy for unresectable rectal cancer. <i>Cancer</i> , 1991 , 67, 2859-66	6.4	83
289	Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome. <i>JAMA Oncology</i> , 2018 , 4, 309-315	13.4	79
288	Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature. <i>Human Pathology</i> , 2012 , 43, 1677-87	3.7	79
287	Neither FDG-PET Nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study. <i>Annals of Surgery</i> , 2013 , 258, 289-95	7.8	78
286	Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2975-84	2.2	77
285	Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 519-28	7.3	77
284	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. <i>Journal of Clinical Oncology</i> , 2016 , 34, 144-50	2.2	76
283	Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. <i>Cancer Research</i> , 2019 , 79, 1047-1053	10.1	73
282	A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014 , 60, 319-24	13.4	72
281	A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. <i>Annals of Oncology</i> , 2002 , 13, 1067-71	10.3	72
280	Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial. <i>JAMA Oncology</i> , 2018 , 4, 783-790	13.4	71
279	A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. <i>Cancer</i> , 2001 , 91, 101-5.4	6.4	70

278	Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. <i>Journal of Clinical Oncology</i> , 2015 , 33, 22-8	2.2	69
277	Overspending driven by oversized single dose vials of cancer drugs. <i>BMJ, The</i> , 2016 , 352, i788	5.9	68
276	Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 62, 1363-70	4	68
275	Complications after preoperative combined modality therapy and radical resection of locally advanced rectal cancer: a 14-year experience from a specialty service. <i>Journal of the American College of Surgeons</i> , 2005 , 200, 876-82; discussion 882-4	4.4	66
274	Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. <i>Annals of Oncology</i> , 2011 , 22, 2604-2609	10.3	64
273	Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 852-871	7.3	63
272	Conservative management of rectal cancer with local excision and postoperative adjuvant therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999 , 44, 841-846	4	63
271	Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. <i>Annals of Surgical Oncology</i> , 2002 , 9, 954-60	3.1	62
270	False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 907-13	7.3	61
269	End points in advanced colon cancer clinical trials: a review and proposal. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3572-5	2.2	61
268	A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. <i>Annals of Oncology</i> , 2008 , 19, 86-91	10.3	60
267	L1CAM defines the regenerative origin of metastasis-initiating cells in colorectal cancer. <i>Nature Cancer</i> , 2020 , 1, 28-45	15.4	59
266	Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2012 , 11, 101-11	3.8	58
265	Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 1540-51	9.7	58
264	Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 78, 1064-72	4	58
263	Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 449-54	7.3	56
262	Pulmonary recurrence predominates after combined modality therapy for rectal cancer: an original retrospective study. <i>Annals of Surgery</i> , 2012 , 256, 111-6	7.8	56
261	Association of family history with cancer recurrence and survival among patients with stage III colon cancer. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 299, 2515-23	27.4	56

260	A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. <i>Cancer</i> , 1994 , 74, 958-61	6.4	56
259	Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 60-67	13.4	55
258	NCCN clinical practice guidelines in oncology. Anal carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010 , 8, 106-20	7.3	53
257	The Impact of Primary Tumor Location on Long-Term Survival in Patients Undergoing Hepatic Resection for Metastatic Colon Cancer. <i>Annals of Surgical Oncology</i> , 2018 , 25, 431-438	3.1	53
256	A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. <i>Journal of the American Academy of Dermatology</i> , 2009 , 61, 614-20	4.5	52
255	Multiparametric MRI in the assessment of response of rectal cancer to neoadjuvant chemoradiotherapy: A comparison of morphological, volumetric and functional MRI parameters. <i>European Radiology</i> , 2016 , 26, 4303-4312	8	51
254	Palliative care in the outpatient oncology setting: evaluation of a practical set of referral criteria. <i>Journal of Oncology Practice</i> , 2011 , 7, 366-70	3.1	51
253	Impact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B 89803. <i>Cancer</i> , 2010 , 116, 957-66	6.4	51
252	Pre-operative combined 5-FU, low dose leucovorin, and sequential radiation therapy for unresectable rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1993 , 25, 821-7	4	51
251	A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. <i>Cancer</i> , 2012 , 118, 4795-800	6.4	50
250	ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	48
249	Adjuvant therapy of colon cancer: current status and future directions. <i>Cancer Journal (Sudbury, Mass)</i> , 2007 , 13, 192-7	2.2	48
248	SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance. <i>Clinical Cancer Research</i> , 2019 , 25, 1948-1956	12.9	48
247	Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations. <i>Clinical Cancer Research</i> , 2017 , 23, 4753-4760	12.9	47
246	TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial. <i>Cancer</i> , 2013 , 119, 4290-8	6.4	47
245	Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 1498-506	9.7	47
244	Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance). <i>PLoS ONE</i> , 2014 , 9, e99816	3.7	46
243	Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome. <i>Annals of Surgical Oncology</i> , 2012 , 19, 2797-804	3.1	46

242	Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). <i>Journal of Clinical Oncology</i> , 2015 , 33, 3598-607	2.2	44
241	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. <i>Cancer Research</i> , 2017 , 77, 6513-6523	10.1	43
240	Bevacizumab 5 mg/kg can be infused safely over 10 minutes. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2691-2695	2.2	43
239	Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 1109-1133	7.3	43
238	Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 5281-9	12.9	42
237	Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2020 , 26, 3271-3279	12.9	41
236	Antibody-based therapies for colorectal cancer. <i>Oncologist</i> , 2005 , 10, 701-9	5.7	41
235	Primary adenocarcinoma of the anus treated with combined modality therapy. <i>Diseases of the Colon and Rectum</i> , 2003 , 46, 1320-4	3.1	40
234	Adjuvant therapy of cancers of the colon and rectum. <i>Surgical Clinics of North America</i> , 2002 , 82, 1035-584	6.4	40
233	Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1789-98	9.7	39
232	Distal cT2N0 rectal cancer: is there an alternative to abdominoperineal resection?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4905-12	2.2	39
231	Colon cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 1238-90	7.3	39
230	Adjuvant therapy for colorectal cancer. <i>Current Problems in Surgery</i> , 1997 , 34, 601-76	2.8	38
229	Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 1998 , 16, 3858-65	2.2	38
228	A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer. <i>Cancer</i> , 1994 , 74, 2224-33	6.4	38
227	Coaltered and Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 1077-1085	12.9	37
226	PKLR promotes colorectal cancer liver colonization through induction of glutathione synthesis. <i>Journal of Clinical Investigation</i> , 2016 , 126, 681-94	15.9	37
225	Epidermal growth factor receptor-negative colorectal cancer: is there truly such an entity?. <i>Clinical Colorectal Cancer</i> , 2005 , 5 Suppl 2, S98-100	3.8	36

224	PD-1 Blockade in Mismatch Repair Deficient, Locally Advanced Rectal Cancer. <i>New England Journal of Medicine</i> ,	59.2	35
223	Marine Ω Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018 , 27, 438-445	4	34
222	Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. <i>Molecular Cancer Research</i> , 2016 , 14, 296-301	6.6	34
221	Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis. <i>Radiotherapy and Oncology</i> , 2013 , 107, 189-94	5.3	34
220	A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma. <i>Annals of Oncology</i> , 2001 , 12, 501-4	10.3	33
219	Serum 25-hydroxy vitamin D and survival in advanced colorectal cancer: a retrospective analysis. <i>Nutrition and Cancer</i> , 2015 , 67, 424-30	2.8	32
218	Evaluation of 18 F-FDG-PET for early detection of suboptimal response of rectal cancer to preoperative chemoradiotherapy: a prospective analysis. <i>Annals of Surgical Oncology</i> , 2011 , 18, 2783-9	3.1	32
217	Non-randomized phase II study to assess the efficacy of pembrolizumab (Pem) plus radiotherapy (RT) or ablation in mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3539-3539	2.2	32
216	Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). <i>Journal of Clinical Oncology</i> , 2018 , 36, 1112-1120	2.2	32
215	Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 98, 1087-1095	4	31
214	Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. <i>Clinical Cancer Research</i> , 2013 , 19, 5777-87	12.9	31
213	Recurrence rates and prognostic factors in ypN0 rectal cancer after neoadjuvant chemoradiation and total mesorectal excision. <i>Annals of Surgical Oncology</i> , 2011 , 18, 3666-72	3.1	31
212	Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa. <i>Cancer</i> , 2006 , 106, 1857-62	6.4	31
211	Clinical and genetic determinants of ovarian metastases from colorectal cancer. <i>Cancer</i> , 2017 , 123, 11346-1143	14.3	30
210	Progress in cancer care: the hope, the hype, and the gap between reality and perception. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5020-1	2.2	30
209	Oral chemotherapeutic agents for colorectal cancer. <i>Oncologist</i> , 2000 , 5, 99-107	5.7	30
208	New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. <i>Lancet Oncology, The</i> , 2001 , 2, 290-7	21.7	30
207	Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance). <i>Clinical Trials</i> , 2019 , 16, 165-175	2.2	30

206	Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2014 , 13, 207-12	3.8	29
205	Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer. <i>Cancer</i> , 2012 , 118, 5414-23	6.4	29
204	ACCO: ASCO core curriculum outline. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2049-77	2.2	29
203	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1929-1937	2.2	28
202	Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4354-63	2.2	28
201	Colon cancer. Clinical practice guidelines in oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2003 , 1, 40-53	7.3	28
200	Study using the NCCN guidelines for palliative care to screen patients for palliative care needs and referral to palliative care specialists. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 1087-96	7.3	27
199	9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma. <i>Cancer</i> , 1997 , 80, 1727-32	6.4	27
198	A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma. <i>Cancer Investigation</i> , 1999 , 17, 195-200	2.1	27
197	A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma. <i>Cancer</i> , 1995 , 75, 2197-202	6.4	27
196	Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). <i>Anticancer Research</i> , 2010 , 30, 4209-17	2.3	27
195	PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis. <i>ELife</i> , 2019 , 8,	8.9	26
194	NCCN Clinical Practice Guidelines Occult primary. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 1358-95	7.3	25
193	Safe and cost effective use of alteplase for the clearance of occluded central venous access devices. <i>Journal of Clinical Oncology</i> , 2002 , 20, 1918-22	2.2	25
192	Phase II trial of gemcitabine in patients with advanced gastric cancer. <i>Cancer</i> , 1994 , 73, 5-7	6.4	25
191	Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug. <i>Oncologist</i> , 2017 , 22, 1102-1106	5.7	24
190	A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2016 , 15, 222-7	3.8	24
189	Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. <i>Clinical Colorectal Cancer</i> , 2013 , 12, 233-8	3.8	24

188	Adjuvant therapy for colorectal cancer. <i>Current Problems in Cancer</i> , 1998 , 22, 11-77	2.3	24
187	How Should We Intervene on the Financial Toxicity of Cancer Care? One Shot, Four Perspectives. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 35-39	7.1	24
186	Understanding and managing chemotherapy-induced diarrhea. <i>The Journal of Supportive Oncology</i> , 2003 , 1, 35-46; discussion 38-41, 45-6		24
185	Colorectal cancer patients with oligometastatic liver disease: what is the optimal approach?. <i>Oncology</i> , 2013 , 27, 1074-8	1.8	24
184	Incidence of chemotherapy-induced amenorrhea in premenopausal women treated with adjuvant FOLFOX for colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2013 , 12, 163-7	3.8	23
183	Adjuvant therapy for colon cancer. <i>Surgical Oncology Clinics of North America</i> , 2010 , 19, 819-27	2.7	23
182	Addition of octreotide functional imaging to cross-sectional computed tomography or magnetic resonance imaging for the detection of neuroendocrine tumors: added value or an anachronism?. <i>Journal of Clinical Oncology</i> , 2011 , 29, e74-5	2.2	23
181	A phase II trial of carboplatin in patients with advanced APUD tumors. <i>Cancer</i> , 1993 , 72, 619-22	6.4	23
180	Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors. <i>Investigational New Drugs</i> , 2015 , 33, 1086-92	4.3	22
179	Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 50-58	7.3	22
178	Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1182-9	2.2	22
177	Colorectal cancer survivors: Needs and preferences for survivorship information. <i>Journal of Oncology Practice</i> , 2014 , 10, e277-82	3.1	22
176	Surgery and high-dose-rate intraoperative radiation therapy for recurrent squamous-cell carcinoma of the anal canal. <i>Diseases of the Colon and Rectum</i> , 2011 , 54, 1090-7	3.1	22
175	The Value of Considering Cost, and the Cost of Not Considering Value. <i>Journal of Clinical Oncology</i> , 2016 , 34, 659-60	2.2	21
174	Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome. <i>Annals of Surgical Oncology</i> , 2004 , 11, 955-61	3.1	21
173	Management of Locally Advanced Rectal Cancer During The COVID-19 Pandemic: A Necessary Paradigm Change at Memorial Sloan Kettering Cancer Center. <i>Advances in Radiation Oncology</i> , 2020 , 5, 687-689	3.3	21
172	Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors. <i>Nature Reviews Clinical Oncology</i> , 2009 , 6, 143-52	19.4	20
171	FDG-PET assessment of rectal cancer response to neoadjuvant chemoradiotherapy is not associated with long-term prognosis: a prospective evaluation. <i>Diseases of the Colon and Rectum</i> , 2012 , 55, 378-86	3.1	20

170	Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. <i>Cancer</i> , 1995 , 75, 769-74	6.4	19
169	Occult primary, version 3.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 969-74	7.3	18
168	Goblet cell carcinoid neoplasm of the appendix: clinical and CT features. <i>European Journal of Radiology</i> , 2013 , 82, 85-9	4.7	18
167	Adjuvant treatment of colorectal cancer. <i>Annual Review of Medicine</i> , 1997 , 48, 191-202	17.4	18
166	Phase I trial of postoperative 5-FU, radiation therapy, and high dose leucovorin for resectable rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1992 , 22, 139-45	4	18
165	Current management of advanced hepatocellular carcinoma. <i>Gastrointestinal Cancer Research: GCR</i> , 2008 , 2, 64-70		18
164	Lymph Node Metastasis Predicts Disease Recurrence in a Single-Center Experience of 70 Stages 1-3 Appendix Cancers: A Retrospective Review. <i>Annals of Surgical Oncology</i> , 2015 , 22, 3613-7	3.1	17
163	Systemic therapy for colon cancer. <i>Gastroenterology Clinics of North America</i> , 2008 , 37, 287-95, ix	4.4	17
162	MicroRNA-203 predicts human survival after resection of colorectal liver metastasis. <i>Oncotarget</i> , 2017 , 8, 18821-18831	3.3	16
161	Metastatic colorectal cancer: is there one standard approach?. <i>Oncology</i> , 2005 , 19, 1147-54; discussion 1154, 1157-8, 1160	1.8	16
160	The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 888-894	9.7	15
159	Universal screening for microsatellite instability in colorectal cancer in the clinical genomics era: new recommendations, methods, and considerations. <i>Familial Cancer</i> , 2017 , 16, 525-529	3	14
158	Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2017 , 22, 780-e65	5.7	14
157	Frequency, characteristics, and correlates of pain in a pilot study of colorectal cancer survivors 1-10 years post-treatment. <i>Pain Medicine</i> , 2013 , 14, 1673-80	2.8	14
156	p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803. <i>Clinical Cancer Research</i> , 2009 , 15, 2116-22	12.9	14
155	KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice. <i>Oncologist</i> , 2011 , 16, 1061-8	5.7	14
154	Evolving treatment of advanced colorectal cancer. <i>Current Oncology Reports</i> , 2010 , 12, 153-9	6.3	14
153	Ten-year results of preoperative radiation followed by sphincter preservation for rectal cancer: increased local failure rate in nonresponders. <i>Clinical Colorectal Cancer</i> , 2006 , 5, 413-21	3.8	14

152	Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2002 , 13, 1490-6	10.3	14
151	Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas. <i>Modern Pathology</i> , 2019 , 32, 110-121	9.8	14
150	Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2018 , 119, 1451-1455	8.7	14
149	Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2200032	2.2	14
148	Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19. <i>JAMA Oncology</i> , 2020 , 6, 1694-1695	13.4	13
147	Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405. <i>Clinical Colorectal Cancer</i> , 2013 , 12, 95-102	3.8	13
146	Irinotecan (Campto) in the treatment of pancreatic cancer. <i>Expert Review of Anticancer Therapy</i> , 2003 , 3, 587-93	3.5	13
145	Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). <i>PLoS ONE</i> , 2018 , 13, e0199244	3.7	12
144	MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial. <i>PLoS ONE</i> , 2014 , 9, e108483	3.7	12
143	ACR Appropriateness Criteria on treatment of anal cancer. <i>Journal of the American College of Radiology</i> , 2007 , 4, 448-56	3.5	12
142	Phase II clinical trial of 13-cis-retinoic acid and interferon-alpha-2a in patients with advanced esophageal carcinoma. <i>Cancer</i> , 1999 , 85, 1213-7	6.4	12
141	A phase I trial of intrahepatic verapamil and doxorubicin. Regional therapy to overcome multidrug resistance. <i>Cancer</i> , 1994 , 74, 2757-64	6.4	12
140	A phase II study of topotecan administered five times daily in patients with advanced gastric cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997 , 20, 621-5	2.7	12
139	Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 400-407	9.7	12
138	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	12
137	Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival. <i>Molecular Cancer Research</i> , 2017 , 15, 708-713	6.6	11
136	Contemporary Validation of a Nomogram Predicting Colon Cancer Recurrence, Revealing All-Stage Improved Outcomes. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz015	4.6	11
135	Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). <i>Journal of the National Cancer Institute</i> , 2019 , 111, 170-179	9.7	11

134	Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments. <i>Journal of Clinical Oncology</i> , 2021 , 39, 950-955	2.2	11
133	A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803. <i>Oncologist</i> , 2017 , 22, 107-114	5.7	10
132	ACR Appropriateness Criteria: local excision in early-stage rectal cancer. <i>Current Problems in Cancer</i> , 2010 , 34, 193-200	2.3	10
131	A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum. <i>Investigational New Drugs</i> , 2004 , 22, 53-61	4.3	10
130	Palliative management of rectal cancer: the roles of chemotherapy and radiation therapy. <i>Journal of Gastrointestinal Surgery</i> , 2004 , 8, 274-6	3.3	10
129	Systemic therapy for metastatic colorectal cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 649-52	7.3	9
128	ACR Appropriateness Criteria: rectal cancer-metastatic disease at presentation. <i>Current Problems in Cancer</i> , 2010 , 34, 201-10	2.3	9
127	Clinical Use of Irinotecan: Current Status and Future Considerations. <i>Oncologist</i> , 1997 , 2, 402-409	5.7	9
126	Colorectal Cancer Treatment: What's Next? (or: Is There Life After EGFR and VEGF?). <i>Gastrointestinal Cancer Research: GCR</i> , 2008 , 2, S20-2		9
125	Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 911-919	2.2	9
124	FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e39-e52	3.8	9
123	Characterization and Clinical Outcomes of DNA Mismatch Repair-deficient Small Bowel Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021 , 27, 1429-1437	12.9	9
122	Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population. <i>Annals of Oncology</i> , 2015 , 26, 950-958	10.3	8
121	Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018 , 27, 1227-1230	4	8
120	Role of expression profiling in carcinoma of unknown primary remains unknown. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2513-4	2.2	8
119	BRAF mutations in colorectal cancer: clinical relevance and role in targeted therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 1456-8	7.3	8
118	Adjuvant Therapy of Colorectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 1997 , 6, 699-722	2.7	8
117	Adjuvant Chemotherapy of Colorectal Cancer. <i>Oncologist</i> , 1996 , 1, 22-29	5.7	8

116	Assessing the Value of Next-Generation Sequencing Tests in a Dynamic Environment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 139-146	7.1	8
115	Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. <i>European Journal of Cancer</i> , 2019 , 111, 82-93	7.5	7
114	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. <i>European Journal of Cancer</i> , 2020 , 130, 63-71	7.5	7
113	Bevacizumab in colorectal cancer: it should have worked. <i>Lancet Oncology, The</i> , 2016 , 17, 1469-1470	21.7	7
112	ACR Appropriateness Criteria on resectable rectal cancer: expert panel on radiation oncology--rectal/anal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 70, 1427-30	7	
111	Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?. <i>Nature Clinical Practice Oncology</i> , 2005 , 2, 20-1		7
110	Another study of how to give fluorouracil?. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3711-2	2.2	7
109	Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer. <i>Anti-Cancer Drugs</i> , 2004 , 15, 219-27	2.4	7
108	A phase I trial of a modified, dose intensive FAMTX regimen (High dose 5-fluorouracil + doxorubicin + high dose methotrexate + leucovorin) with oral uridine rescue 1996 , 78, 1988-1995		7
107	30-day-or-sooner readmissions of gastrointestinal medical oncology patients following cancer center inpatient service discharge: characteristics and preventability 2014 , 42, 34-44		7
106	Pelvic MRI after induction chemotherapy and before long-course chemoradiation therapy for rectal cancer: What are the imaging findings?. <i>European Radiology</i> , 2019 , 29, 1733-1742	8	7
105	Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 2200-2208	12.9	7
104	Value in Colorectal Cancer Treatment: Where It Is Lacking, and Why. <i>Cancer Journal (Sudbury, Mass)</i> , 2016 , 22, 232-5	2.2	6
103	Hospitalists on an inpatient tertiary care oncology teaching service. <i>Journal of Oncology Practice</i> , 2015 , 11, e114-9	3.1	6
102	Doxorubicin and sorafenib for treatment of advanced hepatocellular cancer. <i>Gastroenterology</i> , 2011 , 141, e19-20; author reply e20-1	13.3	6
101	Targeted strategies in the treatment of metastatic colon cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007 , 5, 983-90	7.3	6
100	The role of irinotecan in colorectal cancer. <i>Current Oncology Reports</i> , 1999 , 1, 155-60	6.3	6
99	Surgical Debulking and Intraperitoneal Chemotherapy for Established Peritoneal Metastases From Colon and Appendix Cancer 2001 , 8, 787		6

98	Anal canal cancer. Clinical practice guidelines in oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2003 , 1, 64-8	7.3	6
97	Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. <i>Journal of Geriatric Oncology</i> , 2016 , 7, 422-429	3.6	6
96	Axillary Lymph Node Involvement, a Unique Pattern of Metastasis in BRAF-Mutant Colorectal Cancer. <i>JAMA Oncology</i> , 2015 , 1, 686-7	13.4	5
95	Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a 1 H MRS study. <i>NMR in Biomedicine</i> , 2013 , 26, 204-12	4.4	5
94	Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors. <i>Oncology</i> , 2011 , 81, 65-72	3.6	5
93	First-line treatment of patients with metastatic colorectal cancer: an overview of recent data on chemotherapy plus targeted agents. <i>Clinical Colorectal Cancer</i> , 2008 , 7 Suppl 2, S47-51	3.8	5
92	Is adjuvant therapy for stage II colon cancer worthwhile, and for whom?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2008 , 5, 422-3		5
91	Planned treatment interruptions and chemotherapy-free intervals in the treatment of metastatic colorectal cancer: time to start stopping?. <i>Seminars in Oncology</i> , 2006 , 33, S28-32	5.5	5
90	A phase I trial of cisplatin in hypertonic saline and escalating doses of 5-fluorouracil by continuous intravenous infusion in patients with advanced malignancies. <i>Cancer</i> , 1990 , 66, 1688-91	6.4	5
89	Drug treatment of colorectal cancer. Current status. <i>Drugs</i> , 1991 , 42, 616-27	12.1	5
88	Recommendations for Testing and Treating Outpatient Cancer Patients in the Era of COVID-19. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 820-822	9.7	5
87	Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). <i>JNCI Cancer Spectrum</i> , 2018 , 2, pky017	4.6	5
86	The Cost and Value of Anti-Epidermal Growth Factor Receptor Therapies: Let's Not Be Rash. <i>JAMA Oncology</i> , 2015 , 1, 141-2	13.4	4
85	Translational Considerations on the Outlook of Immunotherapy for Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2015 , 11, 92-97	1	4
84	Discharge to Subacute Rehabilitation Facilities Does Not Benefit Patients Hospitalized With Progressive Gastrointestinal Cancer. <i>Journal of Pain and Symptom Management</i> , 2017 , 54, e4-e7	4.8	4
83	Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer. <i>Investigational New Drugs</i> , 2009 , 27, 366-73	4.3	4
82	Irinotecan: a new agent comes of age. <i>Oncologist</i> , 2001 , 6, 65	5.7	4
81	Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer (CRC): An analysis of 18,399 patients in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4029-4029 ^{2.2}		4

80	Outcomes of ICU Admission of Patients With Progressive Metastatic Gastrointestinal Cancer. <i>Journal of Intensive Care Medicine</i> , 2020 , 35, 297-302	3.3	4
79	Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors. <i>Clinical Cancer Research</i> , 2020 , 26, 1555-1562	12.9	4
78	Can We Afford That CAR? Confronting the Effect of Novel Immunotherapies on Future Health Care Costs. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1381-1382	2.2	4
77	Clinical Use of Irinotecan: Current Status and Future Considerations. <i>Oncologist</i> , 1997 , 2, 402-409	5.7	4
76	Value-Added Decisions in Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019 , 39, 122-131	7.1	3
75	Hospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802). <i>Journal of Geriatric Oncology</i> , 2014 , 5, 230-7	3.6	3
74	Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance).. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101784	2.2	3
73	Total neoadjuvant therapy for locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 662-662		3
72	Looking ahead: what will change in colorectal cancer treatment?. <i>Gastrointestinal Cancer Research: GCR</i> , 2009 , 3, S16-8		3
71	Understanding the Right to Try Act. <i>Clinical Cancer Research</i> , 2020 , 26, 340-343	12.9	3
70	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	3
69	Precision oncology giveth and precision oncology taketh away. <i>Lancet Oncology, The</i> , 2019 , 20, 464-466	21.7	2
68	Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019 , 18, 167-174	3.8	2
67	The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 1692-1695	4	2
66	First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2018 , 36, 860-868	4.3	2
65	BEYOND KRAS: Other markers and potential treatment strategies for KRAS mutant and wild-type patients. <i>Current Treatment Options in Oncology</i> , 2011 , 12, 126-35	5.4	2
64	Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease 2002 , 9, 954		2
63	Management of a patient diagnosed with pancreatic cancer and myelodysplastic syndrome. <i>Gastrointestinal Cancer Research: GCR</i> , 2013 , 6, 56-60		2

62	Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery. <i>JAMA Network Open</i> , 2021 , 4, e2133457	10.4	2
61	A rectal cancer model establishes a platform to study individual responses to chemoradiation		2
60	Occult primary. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008 , 6, 1026-60	7.3	2
59	Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m ² /min. <i>Journal of Oncology Practice</i> , 2016 , 12, e548-53	3.1	2
58	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211020547	5.4	2
57	Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma 1999 , 86, 944		2
56	Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2019 , 2, e1911750	10.4	1
55	Genetic Screening in All Young Patients With Colorectal Cancer?. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1560	2.2	1
54	Commentary: Somatostatin analogs-How we choose, and why. <i>Seminars in Oncology</i> , 2017 , 44, 157-158	5.5	1
53	RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer-Response. <i>Clinical Cancer Research</i> , 2015 , 21, 2188	12.9	1
52	Biologic agents in the treatment of colorectal cancer: an update. <i>Colorectal Cancer</i> , 2014 , 3, 363-374	0.8	1
51	Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors. <i>Cancer Investigation</i> , 2009 , 27, 402-6	2.1	1
50	Targeted therapy for metastatic colorectal cancer: Current challenges and future directions. <i>Current Colorectal Cancer Reports</i> , 2007 , 3, 109-115	1	1
49	The Hardest Weeks of My Life: A Qualitative Study of Experiences, Practice Changes, and Emotional Burden of New York City Oncology Physicians During the COVID-19 Surge in 2020.. <i>JCO Oncology Practice</i> , 2021 , OP2100585	2.3	1
48	A phase II study of induction PD-1 blockade in subjects with locally advanced mismatch repair-deficient rectal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS4123-TPS4123	2.2	1
47	Curative-Intent Treatment for Colorectal Liver Metastases: A Medical Oncologist's Perspective. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012 , 205-8	7.1	1
46	Second- and third-line treatment options for unresectable metastatic colorectal cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2008 , 2, 299-302		1
45	A 40-year-old woman with locally advanced rectal cancer and a solitary liver metastasis. <i>Gastrointestinal Cancer Research: GCR</i> , 2013 , 6, 87-9		1

44	Liver-directed conversion therapy in metastatic colon cancer. <i>Journal of Gastrointestinal Oncology</i> , 2015 , 6, 322-8	2.8	1
43	Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4099-4099	2.2	1
42	PCK1 and DHODH drive colorectal cancer liver metastatic colonization and nucleotide biosynthesis under hypoxia		1
41	Reply to S. Boutayeb et al. <i>JCO Oncology Practice</i> , 2020 , 16, 525	2.3	1
40	In Defense of TNT: A Dynamite Strategy. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1185-1186	2.2	1
39	Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance). <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkab034	4.6	1
38	Adverse event load, onset, and maximum grade: A novel method of reporting adverse events in cancer clinical trials. <i>Clinical Trials</i> , 2021 , 18, 51-60	2.2	1
37	The Landmark Series: Chemotherapy for Non-Metastatic Colon Cancer. <i>Annals of Surgical Oncology</i> , 2021 , 28, 995-1001	3.1	1
36	Current role of bevacizumab in colorectal cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2009 , 7, 375-6	0.6	1
35	Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer.. <i>JAMA Network Open</i> , 2022 , 5, e220145	10.4	1
34	Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps. <i>JAMA Oncology</i> , 2015 , 1, 541-2	13.4	0
33	A 39-year-old female patient with metastatic rectal cancer develops thrombocytopenia. <i>Gastrointestinal Cancer Research: GCR</i> , 2014 , 7, 55-8		0
32	Molecular and cytogenetic characteristics of myeloid malignancies following luminal gastrointestinal cancer. <i>Leukemia Research</i> , 2019 , 82, 19-23	2.7	
31	An elderly man with remote history of metastatic melanoma now with localized pancreas cancer and new liver masses. <i>Journal of Gastrointestinal Oncology</i> , 2017 , 8, 596-602	2.8	
30	Author@ Response. <i>Journal of Pain and Symptom Management</i> , 2018 , 55, e2-e3	4.8	
29	Use of Chemotherapy in the Resection of Liver Metastases of Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2013 , 9, 178-184	1	
28	Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3843-4	2.2	
27	Neuroendocrine Tumors 2014 , 595-600		

26	Treatment Options for Patients With Unresectable Colorectal Cancer With Wild-Type KRAS. <i>Current Colorectal Cancer Reports</i> , 2012 , 8, 170-176	1
25	Unusual Tumors of the Colon, Rectum, And Anus 2012 , 453-463	
24	Evaluation of Bevacizumab in the Adjuvant Treatment of Colon Cancer. <i>Current Colorectal Cancer Reports</i> , 2010 , 6, 109-110	1
23	Oxaliplatin and irinotecan: From advanced to adjuvant therapy of colon cancer. <i>Current Colorectal Cancer Reports</i> , 2006 , 2, 142-148	1
22	Unusual Tumors of the Colon, Rectum and Anus 2006 , 401-409	
21	Irinotecan in the Treatment of Colorectal Cancer 2002 , 513-524	
20	Author reply. <i>Cancer</i> , 2000 , 88, 2195	6.4
19	Recommendation for irinotecan, 5-fluorouracil, and leucovorin as first-line therapy for colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2001 , 1, 82-4	3.8
18	Capecitabine monotherapy in metastatic colorectal cancer [Authors'Reply. <i>Lancet Oncology</i> , 2001 , 2, 400	21.7
17	Peripheral Neuroectodermal Tumor-Ewing® Sarcoma of the Thumb With Local Recurrences and Pleural Metastases After 17 Years: A Unique Clinical Presentation and a Challenging Differential Diagnosis of the So-called Small, Round Cell Neoplasms. <i>International Journal of Surgical Pathology</i> , 1994 , 2, 147-156	1.2
16	Efficacy of bevacizumab-based treatment in early-onset treatment-naïve metastatic colorectal cancer patients: An ARCAD database analysis.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 101-101	2.2
15	Combination chemotherapy: the fallback position?. <i>Gastrointestinal Cancer Research: GCR</i> , 2008 , 2, 154-5	
14	Neoadjuvant Therapy in Clinical Stage II Pancreatic Adenocarcinoma. <i>Gastrointestinal Cancer Research: GCR</i> , 2012 , 5, 169-73	
13	Modified GTX as Second-Line Chemotherapy in Advanced Pancreatic Cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2013 , 6, 115-7	
12	Adjuvant Therapy for Colon Cancer 2002 , 585-596	
11	Actionable alterations (AA) in gastrointestinal (GI) cancers: Rate of detection and receipt of matched therapies (MT).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e15677-e15677	2.2
10	Immediate post-thermal ablation biopsy of colorectal liver metastases to predict oncologic outcomes.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4602-4602	2.2
9	Survival outcomes among older adults (OA) receiving second-line therapy for metastatic CRC (mCRC): 5,289 patients (pts) from the ARCAD Clinical Trials Program.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 7009-7009	2.2

8	Clinical Use of Camptosar (CPT-11). <i>Oncologist</i> , 1997 , 2, 191-191	5.7
7	Advances in systemic therapy for hepatocellular carcinoma 2012 , 1444-1452.e3	
6	Adenocarcinoma of the Colon and Rectum 2013 , 2051-2074	
5	Biologic Agents in the Treatment of Colorectal Cancer: The Last Decade; the Lost Decade?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , e121-e125	7.1
4	Lack of Availability and Efficacy of Phase I and Basket Trials for Patients With Gastrointestinal Cancers. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 438-442	9.7
3	The rate and risk of secondary pelvic malignancies (SPM) in patients treated with definitive radiation for locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 12065-12065	2.2
2	Clinicopathological and molecular characteristics of early-onset stage III colon adenocarcinoma: An analysis of 25 studies with 35,713 patients in the Adjuvant Colon Cancer End Points (ACCENT) database.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3597-3597	2.2
1	Randomized blinded study comparing injection site pain from octreotide long-acting-release (LAR) versus lanreotide during the treatment of well differentiated neuroendocrine tumors (WDNETs).. <i>Journal of Clinical Oncology</i> , 2021 , 39, e16204-e16204	2.2